• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: BIOTRONIK AG, BUELACH, SWITZERLAND ORSIRO (US) 3.0/22; CORONARY DRUG-ELUTING STENT

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

BIOTRONIK AG, BUELACH, SWITZERLAND ORSIRO (US) 3.0/22; CORONARY DRUG-ELUTING STENT Back to Search Results
Model Number 401756
Device Problem Device Dislodged or Dislocated (2923)
Patient Problem Death (1802)
Event Date 01/10/2020
Event Type  Death  
Event Description
After pre-dilatation of a moderate calcified lesion (90 percent stenosis degree) in a mildly tortuous lad an orsiro drug-eluting stent system was selected.The orsiro could not cross the lesion and was removed.The lesion was deflated again and the same device was re-inserted.The orsiro could not cross again.During withdrawal, the stent dislodged and an attempt was made to retrieve the stent with a snare, but unsuccessful.The stent was then adapted to the vessel wall by using different balloon catheters.During the follow-up with the hospital we received the information that the patient passed away.The death was reported as not device related.
 
Manufacturer Narrative
Neither the complaint instrument nor the angiographic material was returned for analysis.Therefore no technical investigation on the subject could be performed.The production documentation was reviewed to establish whether a deviation from the manufacturing process could be the cause for the reported event.Review of the production documentation for the product detailed above verified that the instrument was manufactured according to specifications and fulfilled all the requirements of in-process and final inspection.During final inspection, every stent system undergoes visual inspection to ensure correct stent embedding and homogeneous crimping of the stent.Further, the stent outer diameter is verified to 100 percent and the stent retention force of a defined amount of samples is tested from every lot.Based on the conducted investigations of the device being subject to this complaint, no material or manufacturing related root cause was determined.It should be noted that the ifu warns against re-insertion if the orsiro stent system was removed prior to expansion.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
ORSIRO (US) 3.0/22
Type of Device
CORONARY DRUG-ELUTING STENT
Manufacturer (Section D)
BIOTRONIK AG, BUELACH, SWITZERLAND
ackerstrasse 6
buelach CH-81 80
CH  CH-8180
MDR Report Key9639311
MDR Text Key176714838
Report Number1028232-2020-00450
Device Sequence Number1
Product Code NIQ
UDI-Device Identifier07640130439115
UDI-Public07640130439115
Combination Product (y/n)N
PMA/PMN Number
P170030
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,user f
Type of Report Initial,Followup
Report Date 01/16/2020
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received01/28/2020
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date06/27/2021
Device Model Number401756
Device Catalogue NumberSEE MODEL NO.
Device Lot Number06191067
Was Device Available for Evaluation? No
Date Manufacturer Received04/17/2020
Is This a Reprocessed and Reused Single-Use Device? No
Patient Sequence Number1
Patient Outcome(s) Death;
Patient Age69 YR
-
-